AB Science announces that three clinical abstracts will be

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting

PARIS, May 18, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that the three abstracts reporting on phase 2 studies of masitinib in metastatic colorectal cancer, metastatic esophagogastric adenocarcinoma, and advanced triple negative breast cancer, will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 - June 2 in Chicago, Illinois, US).

  • Abstracts and schedule

The list of abstracts and timing of each presentation is provided below, along with brief study summary.

  • Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase 1b/2 trial

Abstract: #3526 Poster: #18 Poster Session: Gastrointestinal (Colorectal) Cancer Date, Location: Monday, June 1 (8:00 AM - 11:30 AM); S Hall A

Professor Julien Taieb of Hôpital Européen Georges Pompidou, Paris, France, principal investigator of this clinical trial, will present updated efficacy and safety data for this prospective, multicenter, open label phase 2 study testing masitinib in combination with chemotherapies including FOLFIRI. AB Science has recently communicated that masitinib plus FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) in this indication reached a median OS of approximately 18 months and one confirmed complete response, which compares favorably against historic benchmarks (press release 1 dated 18 December 2014). The decision to move to the currently recruiting phase 3 study was based on encouraging preliminary results from phase 2, a decision that is corroborated by these follow-up data.

  • Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase 1b/2 trial

Abstract: #4027 Poster: #136 Poster Session: Gastrointestinal (Noncolorectal) Cancer Date, Location: Monday, June 1 (8:00 AM - 11:30 AM); S Hall A

Professor Aziz Zaanan, of Hôpital Européen Georges Pompidou, Paris, France, a leading investigator on this phase 1b/2 clinical trial, will present the study objectives with updated efficacy and safety data. This was a prospective, multicenter, open-label, randomized, uncontrolled study of masitinib in association with chemotherapy for the treatment of recurrent gastric or gastro-esophageal junction adenocarcinoma. Patients received masitinib in combination with irinotecan, or FOLFIRI, or 5-fluorouracil, after progression to platinum-based first-line chemotherapy. AB Science has recently communicated on preliminary survival data for this indication, which compare favorably to numerous published results for second-line irinotecan treatment (press release 2 dated 02 February 2015 ) . Based on the efficacy data generated from this phase 2 study and the acceptable safety profile of masitinib, AB Science intends to conduct a confirmatory phase 3 trial evaluating masitinib at 6 mg/kg/day in combination with irinotecan in second-line.

  • Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase 1b/2 trial

Abstract: #1070 Poster: #184 Poster Session:  Breast Cancer-Triple-Negative/Cytotoxics/Local Therapy Date; Location: Saturday, May 30 (8:00 AM - 11:30 AM); S Hall A

Professor Mario Campone, of Institut de Cancérologie de l'Ouest, Nantes, France, principal investigator of this clinical trial, will present the study objectives with updated efficacy and safety data. This was a prospective, multicenter, open-label, randomized, uncontrolled, phase 1b/2 study to evaluate efficacy and safety of masitinib in association with chemotherapy for the treatment of advanced triple negative breast cancer (TNBC). Patients received masitinib in combination with carboplatin and/or gemcitabine. AB Science has recently communicated on preliminary survival data for this indication (press release 3 dated 12 March 2015).

A decision to continue the development into phase 3 will be taken once results from an on-going phase 2 study in metastatic breast cancer are known. Regarding this latter phase 2 study in metastatic breast cancer, AB Science recently communicated that the external Data and Safety Monitoring Board (DSMB) had recommended study continuation (press release 4 dated 22 January 2015), indicating that the benefit-risk balance for masitinib was positive based on data available at that time.

  • Comment

" These studies selected at this year's ASCO meeting reflect the diverse potential of masitinib as a novel anticancer agent and continued progress in its clinical oncology development program " commented Professor Olivier Hermine, President of the Scientific Committee of AB Science. " The main cellular targets of masitinib are mast cells and macrophages. Tumor-associated macrophages, mast cell and increased mast cell activity in the tumor microenvironment have been linked to poor prognosis and a protumoral immune response in colorectal cancer, gastric cancer and triple negative breast cancer. Unlike other tyrosine kinase inhibitors, masitinib acts also as an immune therapy the benefit of which is to extend overall survival by controlling the aggressiveness, transformation, and dissemination of the tumors. "

  • References

(1) AB Science press release dated 18 December 2014, 'Follow-up of Phase 2 of Masitinib in Second-Line Metastatic Colorectal Cancer confirms Efficacy in Multiple Survival Endpoints'. Available online at http://www.ab-science.com/file_bdd/content/14...CVFENG.pdf

(2) AB Science press release dated 02 February 2015, 'AB Science Reports Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Advanced Stomach Cancer'. Available online at http://www.ab-science.com/file_bdd/content/14...v05ENG.pdf

(3) AB Science press release dated 12 March 2015, 'AB Science Reports Positive Phase 2 Clinical Study Data of Masitinib in Triple Negative Breast Cancer'. Available online at: http://www.ab-science.com/file_bdd/content/14...BCvENG.pdf

(4) AB Science press release dated 22 January 2015, 'The Data and Safety Monitoring Board recommends continuation of the phase 2 study assessing masitinib in relapsing breast cancer based on safety and efficacy data'. Available online at:   http://www.ab-science.com/file_bdd/content/14...a_vENG.pdf

Status of masitinib clinical development in human medicine

Masitinib is currently developed in 13 phase III indications; 7 in oncology, 3 in inflammatory diseases, and 3 in neurodegenerative diseases. Additionally, a large phase II clinical program is ongoing, mainly in oncology. In case of positive results, phase III studies will be initiated following these phase II studies. Overall, clinical development has been initiated in more than 30 countries, without any licensing agreement. Therefore, AB Science has retained full ownership of masitinib.

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science website: www.ab-science.com .

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

AB Science - Financial Communication & Media Relations investors@ab-science.com

AB Science EN http://hugin.info/155655/R/1922253/689077.pdf

HUG#1922253

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 99

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Luxurious Mark Lane Apartments in Naples, FL

Updated Category News Views 205

Explore the Luxurious Mark Lane Apartments Mark Lane Apartments is a remarkable new residential community that has quickly established itself in the real estate market. A Class A+ Trophy Asset This impressive four-story concrete block building is a true trophy asset, featuring 286 spacious units, each averaging 1,050 square feet. The complex is situated on a generous...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 226

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading
Jericho Wholesale and Shell Unite for Breast Cancer Awareness

Updated Category News Views 184

Jericho Wholesale and Shell Join Forces for a Cause Jericho Wholesale is proud to partner with Shell in the initiative Power Up for Pink Aid this October during Breast Cancer Awareness Month. This exciting campaign aims to assist underserved breast cancer patients and their families through vital financial support while raising awareness for the disease. What is Power Up...

Continue Reading
PMGC Holdings Implements Strategic Reverse Stock Split for Growth

Updated Category News Views 119

PMGC Holdings Announces Reverse Stock Split PMGC Holdings Inc. (NASDAQ: ELAB), based in Newport Beach, California, has recently unveiled an important strategic decision to carry out a 1-for-7 reverse stock split effective soon. This move reflects the company’s commitment to maintaining its compliance with Nasdaq’s listing requirements, which is essential for...

Continue Reading
Lynch Carpenter Takes Action on Anne Arundel Data Incident

Updated Category News Views 270

Lynch Carpenter's Response to the Data Breach Incident Recently, a cybersecurity incident was reported by Anne Arundel Dermatology, revealing that a significant breach of personal data has occurred. This disturbing event is said to have affected the personal information of numerous individuals, raising substantial concerns about data privacy. Details of the Cybersecurity...

Continue Reading